NYSE$ABT

Abbott Laboratories · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Achieved strong double-digit earnings growth and raised guidance.

Abbott announced strong Q3 2020 financial results, driven by innovation and delivery despite challenging conditions. The company's new product pipeline remained highly productive, positioning it well to finish the year with momentum.

  • Worldwide sales increased 9.6 percent on a reported basis and 10.6 percent on an organic basis.
  • Worldwide Nutrition sales increased 2.6 percent on a reported basis and 4.1 percent on an organic basis.
  • Worldwide Diagnostics sales increased 38.2 percent on a reported basis and increased 38.8 percent on an organic basis, with $881 million in global COVID-19 testing-related sales.
  • Worldwide Medical Devices sales increased 3.4 percent on a reported basis and increased 2.6 percent on an organic basis.

Headline financials

Total Revenue

$8.85B

Previous: $8.08B+9.6%
EPS (adj)

$0.98

Previous: $0.84+16.7%
Capital Expenditures

-$1.5B

Previous: -$1.2B-24.4%
Free Cash Flow

-$266M

Previous: -$244M-9.0%
Net Income

$1.23B

Previous: $960M+28.3%
Operating Income

$1.5B

Previous: $1.2B+24.8%
Gross Profit

$4.89B

Previous: $4.72B+3.6%
Cash & Equivalents

$4.48B

Previous: $4.09B+9.5%
Total Assets

$69B

Previous: $68.5B+0.7%
Stock-Based Comp

$100M

Previous: $94M+6.4%

Revenue & EPS history

Abbott · Revenue · Quarterly

$8.85B

Q3 2020+9.6%vs Q3 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Abbott · $6.7B total across 2 segments · Q3 2023

  • Medical Devices
    $4.25B+17.5%
  • Diagnostics
    $2.45B-33.3%

Forward guidance

Abbott projects full-year 2020 diluted earnings per share from continuing operations under GAAP of at least $2.35. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $3.55 for full-year 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

+0.6%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+1.1%

Avg return

30 days after

61%

45 / 74 earnings

Positive

+10.3%

Q3 2013

Best reaction

-9.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%-8.7%-16.8%
Q4 2025-9.9%-10.3%-7.1%
Q3 2025-2.9%-2.8%-2.0%
Q2 2025-0.1%+1.4%+3.3%
Q1 2025+2.8%+2.9%+6.8%
Q4 2024+0.8%+10.8%+15.5%
Q3 2024+1.6%+0.8%-0.1%
Q2 2024-2.5%-0.7%+6.0%
Q1 2024-3.6%-2.0%-4.7%
Q4 2023-1.4%-0.5%+4.8%
Q3 2023+3.6%+4.0%+8.0%
Q2 2023+6.5%+5.3%-3.3%
Q1 2023+6.0%+6.0%+4.6%
Q4 2022-1.3%-2.4%-10.7%
Q3 2022-9.3%-6.4%-1.1%
Q2 2022+0.7%-1.3%+0.1%
Q1 2022+2.8%+0.0%-5.6%
Q4 2021-2.3%+3.4%-0.7%
Q3 2021+4.8%+6.1%+6.3%
Q2 2021+1.5%+0.7%+6.2%
Q1 2021-1.5%-1.0%-5.4%
Q4 2020+4.9%+6.8%+4.4%
Q3 2020+1.0%+0.6%+2.3%
Q2 2020+2.6%+1.5%+3.4%
Q1 2020+5.6%+3.4%-1.2%
Q4 2019+1.1%-0.2%-2.5%
Q3 2019+0.5%-0.4%+4.5%
Q2 2019+5.5%+5.9%+1.9%
Q1 2019-3.2%-2.4%-0.5%
Q4 2018-0.9%-3.4%+6.5%
Q3 2018-4.0%-3.4%+1.5%
Q2 2018+1.6%+0.6%+3.1%
Q1 2018+0.1%-1.6%+3.2%
Q4 2017+6.7%+6.9%+0.8%
Q3 2017+1.7%+1.9%+0.9%
Q2 2017+2.9%+2.8%-1.4%
Q1 2017+1.3%+1.6%-0.6%
Q4 2016+1.6%+1.6%+12.5%
Q3 2016-1.0%-1.8%-3.2%
Q2 2016+3.0%+3.9%+5.8%
Q1 2016+0.1%
Q4 2015-6.5%
Q3 2015+4.2%
Q2 2015+2.9%
Q1 2015+2.8%
Q4 2014+3.1%
Q3 2014+0.1%
Q2 2014+1.8%
Q1 2014+2.5%
Q4 2013-4.3%
Q3 2013+10.3%
Q2 2013+0.0%
Q1 2013+1.3%
Q4 2012-0.3%
Q3 2012-7.6%
Q2 2012-1.0%
Q1 2012-1.5%
Q4 2011-0.2%
Q3 2011-0.4%
Q2 2011-0.1%
Q1 2011+0.9%
Q1 2008+1.4%
Q4 2010+1.4%
Q3 2010-0.8%
Q2 2010+0.7%
Q1 2009-1.4%
Q1 2010+0.9%
Q4 2007-1.1%
Q4 2009-1.1%
Q3 2008+1.4%
Q3 2009+1.4%
Q2 2009+2.1%
Q4 2008+2.1%
Q2 2008+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro